Comparative pharmacokinetics of two atenolol products

Journal of Food and Drug Analysis

Volumn 11, Issue 1, 2003, Pages 4-7

  Wu, Fe Lin Lin ^a   Chen, Po Fen ^a   Lee, Yi Jen ^b   Chen, Russel Rhei Long ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^c TAJEN INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

Atenolol; Comparative bioavailability; Pharmacokinetics

Indexed keywords

ATENOLOL; ATEOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 0038811624     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. "AHFS Drug Information". 1999. pp. 1388-1392. American Society of Health-System Pharmacists. Bethesda, U.S.A.
2. Wadworth, A. N., Murdoch, D., Brogden, R. N. 1991. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 42: 468-510.
3. McLeod, A. A., Shand, D. G. 1982. Atenolol: a long-acting beta-adrenoceptor antagonist. Ann Intern Med. 96: 244-245.
4. Wan, S. H., Koda, R. T., Maronde, R. F. 1979. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol. 7: 569-574.
5. Leonetti, G., Terzoli, L., Bianchini, C., Sala, C., Zanchetti, A. 1980. Time-course of the antihypertensive action of atenolol: comparison of response to first dose and to maintained oral administration. Eur J Clin Pharmacol. 18: 365-374.
6. Wu, F. L., Chen, P. F., Chen, R. R. L. 2002. Comparative Bioavailability and Pharmacokinetics of Two Atenolol Products. Chin Pharm J 54:175-180.
7. Melander, A., Stenberg, P., Liedholm, H., Schersten, B., Wahlin-Boll, E. 1979. Food-induced reduction in bioavailability in atenolol. Eur J Clin Pharmacol. 16: 327-330.
8. Brown, H. C., Carruthers, S. G., Johnston, G. D., Kelly, J. G., McAinsh, J., McDevitt, D. G., Shanks, R. G. 1976. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 20: 524-534.
9. Koda, R. T., Maronde, R. F., Wan, S. H., et al. 1977. Kinetics of absorption and excretion of atenolol (ICI 66, 082) from single intravenous and oral doses in humans. Clin Pharmacol Ther. 21: 108.
10. Orville, H. W., Edwin, N. A., William, D. M. 1978. Rapid determination of atenolol in human plasma and urine by high-pressure liquid chromatography. J Pharm Sci. 67: 1033-1035.
11. Winkler, H., Ried, W., Lemmer, B. 1982. High-performance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue. J Chromatogr. 228: 223-34.
12. Amery, A., De Plaen, I.F., Linjnew, P., McAinsh, J., Reybrouck, T. 1977. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 21: 691.
13. Kirch W, Gorg KG. Clinical pharmacokinetics of atenolol - a review. 1982. Eur J Drug Met Pharmacokinet 7: 81-91.